The costs and benefits of regulations for reimbursement of new drugs

Health Policy

Volumn 79, Issue 2-3, 2006, Pages 337-344

  Lundkvist, Jonas ^a   Jönsson, Bengt ^b   Rehnberg, Clas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Costs; Drug authorisation; Drugs; Finland; Reimbursement; Sweden

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG UTILIZATION; FINLAND; HEALTH CARE POLICY; PROSPECTIVE PRICING; REIMBURSEMENT; STATISTICAL SIGNIFICANCE; STATISTICS; SWEDEN;

COST-BENEFIT ANALYSIS; DRUG APPROVAL; ECONOMICS, PHARMACEUTICAL; FINLAND; REIMBURSEMENT MECHANISMS; STATE MEDICINE; SWEDEN;

EID: 33749530513     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2006.02.004     Document Type: Article

References (13)

1. Hahn R. Governmental analysis of the benefits and costs of regulation. Journal of Economic Perspectives 12 4 (1998) 201-210
2. Andersson F. The international diffusion of new chemical entities. Dissertation. Linköping, Sweden: University of Linköping; 1990.
3. Drummond M., Brown R., Fendrick A.M., Fullerton P., Neumann P., et al. Use of pharmacoeconomics information-report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health 6 4 (2003) 407-416
4. Drummond M., Jonsson B., and Rutten F. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 40 3 (1997) 199-215
5. Johannesson M. Economic evaluation of drugs and its potential uses in policy making. Pharmacoeconomics 8 3 (1995) 190-198
6. Lundkvist J., Jonsson B., and Rehnberg C. Cost-effectiveness of new drugs-a systematic review of published evidence for NCE drugs introduced on the Swedish market 1987-2000. International Journal of Technology Assessment in Health Care 21 2 (2005) 187-193
7. Stoykova B., Drummond M., Barbieri M., and Kleijnen J. The lag between effectiveness and cost-effectiveness evidence of new drugs Implications for decision-making in health care. European Journal of Health Economics 4 4 (2003) 313-318
8. Johannesson M. Economic evaluation of health care and policymaking. Health Policy 33 3 (1995) 179-190
9. Rutten F. Economic evaluation and health care decision-making. Health Policy 36 3 (1996) 215-229
10. Rosen A., and Beermann M. Rating innovative therapeutic benefits of medicines licensed in Sweden 1987-1997. International journal of pharmaceutical medicine 13 (1999) 123-126
11. National Corporation of Swedish Pharmacies. Sale statistics; 2004.
12. Eklund M, Persson B. Pharmaceutical pricing in a regulated market. Stockholm: Department of Economics, Stockholm School of Economics; 1999.
13. Council Directive 89/105/EEC; 1988.